Cargando...
Development of 'synthetic lethal' strategies to target BRCA1-deficient breast cancer
Recent clinical trials demonstrating the efficacy of poly(ADP-ribose) polymerase (PARP) inhibitors for the treatment of BRCA1-deficient breast cancer have provided support for the 'synthetic lethal' concept of targeted cancer therapeutics. A new study provides further preclinical validatio...
Gardado en:
| Autor Principal: | |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado: |
BioMed Central
2009
|
| Assuntos: | |
| Acceso en liña: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2790845/ https://ncbi.nlm.nih.gov/pubmed/19804613 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/bcr2362 |
| Tags: |
Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|